Download PDF

1. Company Snapshot

1.a. Company Description

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors.Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers.


The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer.HOOKIPA Pharma Inc.has a collaboration with Gilead Sciences, Inc.


to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus.The company was incorporated in 2011 and is headquartered in New York, New York.

Show Full description

1.b. Last Insights on HOOK

Negative drivers behind HOOKIPA Pharma's recent performance include uncertainty surrounding its proposed merger with Poolbeg Pharma, as evidenced by the flurry of regulatory filings and statements. The company's largest shareholder, Gilead Sciences, has thrown its support behind the deal, but the associated fundraising and disclosure requirements may be weighing on investor sentiment. Additionally, the lack of recent earnings updates or significant pipeline developments may be contributing to the company's stagnant performance.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead

Oct -31

Source: globenewswire.com

Card image cap

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

Jul -18

Source: globenewswire.com

Card image cap

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)

Feb -20

Source: globenewswire.com

Card image cap

HOOKIPA Pharma Inc - FORM 8 (OPD)

Jan -08

Source: globenewswire.com

Card image cap

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

Jan -07

Source: globenewswire.com

Card image cap

Gilead backs proposed Poolbeg Pharma's proposed tie-up with HOOKIPA

Jan -07

Source: proactiveinvestors.co.uk

Card image cap

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

Jan -02

Source: globenewswire.com

Card image cap

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

Nov -11

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.27%)

6. Segments

Pharmaceutical Products

Expected Growth: 10.27%

HOOKIPA Pharma Inc.'s 10.27% growth in Pharmaceutical Products is driven by increasing demand for novel immunotherapies, strategic partnerships, and advancements in arenavirus-based vaccine technologies. Additionally, the company's focus on infectious diseases and oncology treatments, as well as its strong pipeline of candidates, contribute to its growth momentum.

7. Detailed Products

HB-101

HB-101 is a prophylactic vaccine candidate against cytomegalovirus (CMV) based on HOOKIPA's proprietary arenavirus-based vaccine platform, VaxWave.

HB-201

HB-201 is a therapeutic vaccine candidate against human papillomavirus 16-positive (HPV16+) cancers based on HOOKIPA's proprietary arenavirus-based vaccine platform, VaxWave.

HB-301

HB-301 is a prophylactic vaccine candidate against SARS-CoV-2 based on HOOKIPA's proprietary arenavirus-based vaccine platform, VaxWave.

HB-401

HB-401 is a therapeutic vaccine candidate against human immunodeficiency virus (HIV) based on HOOKIPA's proprietary arenavirus-based vaccine platform, VaxWave.

8. HOOKIPA Pharma Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

HOOKIPA Pharma Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for the diseases it targets. However, the company's focus on novel RNA-based therapies and its proprietary arenavirus-based vaccine technology may provide some protection against substitutes.

Bargaining Power Of Customers

HOOKIPA Pharma Inc. has a low bargaining power of customers due to its focus on rare and orphan diseases, where patients have limited treatment options. This gives the company some pricing power and reduces the bargaining power of customers.

Bargaining Power Of Suppliers

HOOKIPA Pharma Inc. has a moderate bargaining power of suppliers due to its reliance on contract manufacturers and suppliers of raw materials. However, the company's proprietary technology and intellectual property may give it some negotiating power with suppliers.

Threat Of New Entrants

HOOKIPA Pharma Inc. faces a high threat of new entrants due to the growing interest in RNA-based therapies and the increasing availability of funding for biotech startups. New entrants may challenge HOOKIPA's market position and intellectual property.

Intensity Of Rivalry

HOOKIPA Pharma Inc. operates in a moderately competitive industry, with several established players and startups developing RNA-based therapies. However, the company's focus on rare and orphan diseases may reduce the intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 6.80%
Debt Cost 4.81%
Equity Weight 93.20%
Equity Cost 8.53%
WACC 8.28%
Leverage 7.30%

11. Quality Control: HOOKIPA Pharma Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Nektar

A-Score: 4.5/10

Value: 8.0

Growth: 4.2

Quality: 4.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Werewolf Therapeutics

A-Score: 3.9/10

Value: 7.4

Growth: 4.4

Quality: 5.8

Yield: 0.0

Momentum: 5.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
HOOKIPA Pharma

A-Score: 3.6/10

Value: 9.2

Growth: 5.8

Quality: 4.8

Yield: 0.0

Momentum: 0.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Absci

A-Score: 2.8/10

Value: 6.6

Growth: 2.7

Quality: 3.8

Yield: 0.0

Momentum: 2.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Capricor Therapeutics

A-Score: 2.7/10

Value: 6.6

Growth: 4.3

Quality: 4.9

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Xencor

A-Score: 2.5/10

Value: 7.2

Growth: 1.1

Quality: 4.4

Yield: 0.0

Momentum: 0.0

Volatility: 2.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.87$

Current Price

0.87$

Potential

-0.00%

Expected Cash-Flows